IIS Aragon

2 March, 2026

A breakthrough from Aragon opens new avenues of immunotherapy for rare blood diseases

A preclinical study by the IIS Aragón demonstrates, for the first time, the viability of a CAR-T therapy aimed at myeloproliferative neoplasms (rare blood diseases with limited therapeutic options).
27 February, 2026

FEDER promotes the transfer of the IMPaCT-GENÓMICA genetic diagnostic search program to the National Health System

The XV CIBERER Conference "Research is Progress", held yesterday with the participation of FEDER, was the Central Event of Rare Disease Day in Aragon.
25 February, 2026

The Cuenca Villoro Foundation's 2025 Grant supports a project by the IIS Aragón on high-risk neuroblastoma

Endowed with 50.000 euros, this year's call supports the project led by Ariel Gaspar Ramírez Labrada, from the Immunotherapy, Inflammation, Infection and Cancer (I3C) group of the IIS Aragón.
24 February, 2026

Healthcare professionals in Zaragoza II present more than 80 research and innovation projects to improve the patient experience

The 4th Conference included the participation of representatives from the Government of Aragon, the IIS Aragon, professionals from the Zaragoza II sector and the Roche Farma entity.
23 February, 2026

Calatayud will host the 5th Meeting of Young Cancer Researchers (EJIC)

The initiative of the Spanish Association Against Cancer will bring together 30 predoctoral researchers from all over the country in a training, scientific and outreach forum that celebrates its fifth anniversary.
20 February, 2026

The second edition of the 'HumanizAR and CuidAR Awards' is now open to recognize projects that are transforming healthcare in Aragon.

The General Directorate of Care and Humanization is promoting this call for proposals with the support of the IIS Aragón and the sponsorship of Roche Farma Spain.
20 February, 2026

Farmaindustria and REGIC sign an agreement that reinforces their commitment to improving clinical research

The IIS Aragón coordinates the Clinical Research Interest Group of REGIC, a key space for joint work with the innovative pharmaceutical industry.